HeartMate 3—a “Step” in the right direction

JOURNAL OF THORACIC DISEASE（2017）

引用 7|浏览6

暂无评分

摘要

Earlier in this decade, the concerning reports regarding high rates of complications for left ventricular assist devices (LVADs) led to the interruption and finally the premature completion of the REVIVE-IT (Randomized Evaluation of VAD InterVEntion before Inotropic Therapy) trial (1).

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要